Deficient bone metabolism predicts clinical outcome. (A) Osteocalcin (OCN) levels measured in the peripheral blood of controls (n = 31) and AML patients (n = 58). Data are shown as mean ± SEM. **P < .01 (determined by Mann-Whitney U test). (B) Bone marrow blast infiltration in patients with osteocalcin level ≤11 ng/mL (OCN-Low, n = 16) and osteocalcin levels >11 ng/mL (OCN-High, n = 26). Data are shown as mean ± SEM. *P < .05 (determined by Mann-Whitney U test). (C) Peripheral blood blast percentage in patients with OCN-Low (n = 24) and OCN-High (n = 32). Data are shown as mean ± SEM. ****P < .0001 (determined by Mann-Whitney U test). (D) Overall survival of OCN-Low (n = 24) and OCN-High (n = 34). *P = .0339 (determined by log-rank test). (E) Relapse-free survival of AML patients receiving curative-intent treatment with OCN-Low (n = 14) and OCN-High (n = 20). P = .1105 (determined by log-rank test).